Know Labs, Inc. (NYSE American: KNW), an emerging developer of
non-invasive medical diagnostic technology, today shared an update
on its strategic partnerships with leading experts in data science,
sensor technology, product design and regulatory affairs. These
strategic partners collectively accelerate Know Labs’ progress
toward the FDA clearance process for the world’s first non-invasive
glucose monitoring medical devices.
“Doing something that’s never been done before not only takes
time and thoughtful attention to detail – it takes industry experts
with high levels of experience and expertise,” said Ron Erickson,
CEO and Chairman at Know Labs. “We are fortunate to have
world-class respected experts working alongside our own talented
Know Labs team, to help accelerate our progress on data science,
product design and the regulatory process, as we develop medical
devices that we believe will transform patient care.”
With 30 years in medical device and high-tech design and
development, Dr. Reza Kassayan, MD, BSEE has been lead
designer and system architect for numerous commercially successful
large-scale projects. He specializes in ultra-miniaturized embedded
electronics for medical devices and has been assisting the Know
Labs team to further refine Know Labs’ Bio-RFID™ sensor. “It’s
inspiring to see the potential impact for this novel application of
radio frequency spectroscopy. Having engineered other life-changing
non-invasive medical devices, I’m thrilled to be supporting this
development,” Kassayan said.
Igor Institute, a product development firm specializing
in mechanical, electrical, and firmware engineering known for its
work with multiple consumer brands, has been working with Know Labs
since 2018 on Bio-RFID sensor development and optimization. Igor
works closely with Know Labs’ engineering team and is a
foundational partner of high importance to the platform. Aren
Kaser, Co-Founder and CEO of Igor Institute shared, “It is in our
DNA to support hardware development from early stage inception to
taking the most complex products to-market, and it’s been
incredible to aim our expertise in mechanical, electrical, and
firmware engineering to support the development of the first
functioning prototype of the Know Labs non-invasive glucose
monitor.”
The respected industrial design firm behind successful products
such as Nest®, Roku® and Willow®, Bould Design has been
providing Know Labs with design support on an updated prototype of
Know Labs’ non-invasive glucose monitoring medical devices. “With
function at the core of our design principles, we're excited to
help design a first-of-its-kind medical device with the potential
to improve so many people's lives,” said Fred Bould, Principal
Partner and Design Director, Bould Design.
Edge Impulse, the industry-leading development toolkit
for machine learning, is collaborating with Know Labs to accelerate
Bio-RFID’s algorithm refinement, an essential step for interpreting
its existing robust data set and ultimately supporting large-scale
clinical trials. Edge Impulse has partnered with companies in
similar stages of development across a variety of fields in health,
health wearable technology, agriculture and infrastructure. “We’ve
spent the last six months working alongside Know Labs’ software
team to accelerate algorithm development for their non-invasive
glucose monitor and are reminded each day how incredible it is to
demonstrate algorithm performance in such novel data,” said Zach
Shelby, co-founder and CEO of Edge Impulse.
A medical device consulting firm, NOVUS Management Group
LLC, has been providing regulatory systems and strategy
guidance to Know Labs to prepare the company for the FDA clearance
process. Novus has supported the application and approval of more
than 30 products through the FDA.
As previously announced, Racer Technology, a leading
medical device Contract Manufacturing and wearables manufacturer
based in Singapore, will manufacture the KnowU and UBand devices.
Racer provides a world-class manufacturing facility and materials
and has supported several FDA-approved devices from companies
including Medtronic®, Boston Scientific Corporation®, and
Bio-Rad®.
In 2023, Know Labs will prioritize external validation of its
Bio-RFID technology in detecting and measuring glucose and other
analytes in the body non-invasively at high levels of accuracy. The
company will also bring on new technical and scientific advisory
board members in the coming months and will continue working with
existing advisors and diabetes experts, as it brings the Bio-RFID
technology and non-invasive diagnostic devices to market. For more
information on Know Labs, visit www.knowlabs.co.
Notice of Non-Affiliation and Disclaimer
Nest® is a registered trademark of Nest Labs, Inc., ROKU® is a
registered trademark of Roku, Inc., Willow® is a registered
trademark of Willow Innovations, Inc., Medtronic® is a registered
trademark of Medtronic, Inc., Boston Scientific Corporation® is a
registered trademark of Boston Scientific Corporation, Bio-Rad® is
a registered trademark of Bio-Rad Laboratories Inc. Know Labs is
not affiliated, associated, authorized, endorsed by, or in any way
officially connected with Nest, Roku, Willow, Medtronic, Boston
Scientific, or Bio-Rad, or any of its subsidiaries or its
affiliates.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the
NYSE American Exchange under the stock symbol “KNW.” The Company’s
technology uses spectroscopy to direct electromagnetic energy
through a substance or material to capture a unique molecular
signature. The Company refers to its technology as Bio-RFID™. The
Bio-RFID technology can be integrated into a variety of wearable,
mobile or bench-top form factors. This patented and patent-pending
technology makes it possible to effectively identify and monitor
analytes that could only previously be performed by invasive and/or
expensive and time-consuming lab-based tests. The first application
of our Bio-RFID technology will be in a product marketed as a
non-invasive glucose monitor. It will provide the user with
real-time information on blood glucose levels. This product will
require U.S. Food and Drug Administration clearance prior to its
introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of Know Labs, Inc., its directors or its officers with
respect to, among other things: (i) financing plans; (ii) trends
affecting its financial condition or results of operations; (iii)
growth strategy and operating strategy; and (iv) performance of
products. You can identify these statements by the use of the words
“may,” “will,” “could,” “should,” “would,” “plans,” “expects,”
“anticipates,” “continue,” “estimate,” “project,” “intend,”
“likely,” “forecast,” “probable,” “potential,” and similar
expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, many of which are beyond Know
Labs, Inc.’s ability to control, and actual results may differ
materially from those projected in the forward-looking statements
as a result of various factors. These risks and uncertainties also
include such additional risk factors as are discussed in the
Company’s filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K for the fiscal year ended
September 30, 2022, Forms 10-Q and 8-K, and in other filings we
make with the Securities and Exchange Commission from time to time.
These documents are available on the SEC Filings section of the
Investor Relations section of our website at www.knowlabs.co. The
Company cautions readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
The Company undertakes no obligation to update any forward-looking
statement to reflect events or circumstances after the date on
which such statement is made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230202005338/en/
For Know Labs Media Inquiries Contact: Linhart PR Kelly
Brown kbrown@linhartpr.com Ph. (303) 951-2552
Know Labs, Inc. Contact: Jordyn Hujar jordyn@knowlabs.co
Ph. (206) 629-6414
Know Labs (AMEX:KNW)
Historical Stock Chart
From Aug 2024 to Sep 2024
Know Labs (AMEX:KNW)
Historical Stock Chart
From Sep 2023 to Sep 2024